In a restructuring the company projects will annually save $80 million, Emergent is shuttering its Baltimore drug substance manufacturing facility and Rockville, Md., drug product facility.
The drugmaker, which manufactures Narcan nasal spray, is also reducing its workforce by about 300 employees, eliminating about 85 empty positions and creating a chief science officer role.
The restructuring is expected to cost between $18 million and $21 million.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.